Philips provided an update on the comprehensive test and research program of its subsidiary Philips Respironics, following the voluntary recall notification/field safety notice to address potential health risks related to the polyester-based polyurethane, or PE-PUR, sound abatement foam in specific CPAP, BiPAP and mechanical ventilator devices. Following previous updates in December 2021 and June, additional test results and assessments have now been completed for the first-generation DreamStation devices. These devices have not been exposed to ozone cleaning in line with the instructions for use. The test and research program has been conducted together with five independent, certified testing laboratories, and the results have been reviewed and assessed by third-party qualified experts and Philips Respironics, as well as an external medical panel.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PHG:
- PHG Rises after Tests Show Recalled Device Unlikely to be Harmful
- Philips provides update on completed set of test results for first-generation DreamStation sleep therapy devices
- Philips in research deal with MagCorp to explore magnets for MR scanners
- Philips launches compact ultrasound system at RSNA 2022
- Philips advances AI-powered diagnostic systems and transformative workflow solutions at RSNA 2022